FMP
SIGA Technologies, Inc.
SIGA
NASDAQ
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
6 USD
0.06 (1%)
We are unable to load the chart at this time.
Dr. Diem Nguyen M.B.A., Ph.D.
Healthcare
Drug Manufacturers - Specialty & Generic
NASDAQ
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
0001010086
US8269171067
826917106
31 East 62nd Street
212 672 9100
US
45
Sep 10, 1997
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001010086
NASDAQ
Drug Manufacturers -...
Healthcare
826917106
US8269171067
US
6
0.89
532.77k
428.43M
-
4.26-12.83
27.8
-
-
-
-
5
-
https://www.siga.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.